AMLX vs NVO
AMLX: Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric hypoglycemia. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | AMLX | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.70 | $48.19 | |
| Market cap as of 2026-07-23 | $2.0B | $219.8B | |
| P/E as of 2026-07-23 | n/a | 11.78 | |
| PEG as of 2026-07-23 | n/a | 16.16 | |
| Net margin as of 2026-07-23 | -94.6% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +82.8% | +81.8% | AMLX higher |
| Operating margin as of 2026-07-23 | -99.2% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | -55.7% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | -50.7% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.72 | AMLX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.1% | |
| Dividend yield as of 2026-07-23 | n/a | +3.7% | |
| Beta as of 2026-07-23 | -0.20 | 1.85 | |
| 1-year return as of 2026-07-22 close | +125.3% | -23.8% | AMLX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.